Skip to main content
. 2014 Aug 7;1(8):540–549. doi: 10.18632/oncoscience.73

Figure 2. Computerized tomography (CT) demonstrating response to treatment with combination cetuximab, erlotinib, and bevacizumab in a patient with KRAS wild-type colorectal cancer who had received prior cetuximab and bevacizumab.

Figure 2

A decrease in tumor size of 45% by RECIST was observed, and the patient received treatment for 6 months. Panel A demonstrates a liver metastasis at baseline, and Panel B demonstrates the tumor after 6 months of treatment.